i-Lumen Scientific

What i-Lumen Scientific does

i-Lumen Scientific, Inc. is a Bloomington, Minnesota-based clinical-stage medical device company developing the i-LUMEN AMD System, a non-invasive bioelectric therapy intended to restore retinal electrophysiology in patients with intermediate to advanced dry age-related macular degeneration (AMD). The device delivers a proprietary dual waveform (monophasic and biphasic) microcurrent through the closed eyelid during an in-office treatment, with the stated mechanism of restoring the retinal pigment epithelium's transepithelial potential (TEP) and increasing production of pigment epithelium-derived factor (PEDF), a signaling protein associated with photoreceptor survival. The therapy does not require anesthesia or incisions and is administered in 7 treatments over approximately 2 months, with pilot data showing a 9.6-letter mean improvement in best-corrected visual acuity versus 6.3 letters reported for a competing energy-based dry AMD device.

The company is currently conducting the i-SIGHT2 pivotal trial across the United States, United Kingdom, Australia, and New Zealand, targeting 120 participants with primary endpoint data expected in early 2028. The U.S. arm was enabled by an FDA Investigational Device Exemption (IDE) approval received in March 2026, with the first U.S. patient randomized at Texas Retina Associates in July 2026. Earlier clinical work includes the multicenter i-SIGHT pilot, a decade-long open-label evaluation (2014–2024), preclinical studies at Schepens Eye Institute, and computational modeling of current distribution across ocular tissues. The scientific foundation spans more than 30 years of bioelectric-stimulation research, led by CEO John Velure (prior neurostimulation exits including Neurotech and Compex Technologies) and supported by an advisory board that includes senior ophthalmology and electrophysiology researchers from Mayo Clinic, Harvard/Mass Eye and Ear, and Kings College.

i-Lumen Scientific is pre-commercial: the device is investigational only, no pricing exists, and revenue is not yet generated. The go-to-market model, once approved, is enterprise/field sales targeting ophthalmologists and retina specialists who treat dry AMD patients across in-office clinical settings in the U.S. and international markets. To date the company has raised approximately $18.8 million in disclosed funding (a $750,000 round in 2020 and approximately $18.0 million in 2022), with a Series B referenced on the investor site but not yet disclosed. Board composition includes Robert Warner (former Alcon Laboratories President) and Stella Robertson of Bios Partners, providing sector-experienced governance. The strategic backdrop is reinforced by Alcon's $850 million acquisition of a competing bioelectric dry AMD device (Valeda) in late 2025, establishing a comparable exit valuation benchmark.

Name

i-Lumen Scientific

Legal name

i-Lumen Scientific, Inc.

Website

https://i-lumen.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

i-Lumen Scientific is a clinical-stage medical device company developing the i-LUMEN AMD System, a non-invasive bioelectric stimulation therapy for intermediate to advanced dry age-related macular degeneration, currently in a multinational pivotal trial targeting ophthalmologists and retina specialists.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

akta.pro secondary industry

Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)

Keywords

• Bioelectric stimulation therapy
• Dry AMD treatment
• Retinal electrophysiology therapy
• Non-invasive medical devices
• Ophthalmic microcurrent therapy

Headquarters

HQ city

Bloomington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-commercial (Clinical Stage): i-Lumen Scientific is a clinical-stage company. The i-LUMEN AMD System is an investigational device limited by Federal (or United States) law for investigational use only. The company is currently conducting the i-SIGHT2 pivotal clinical trial and has not yet commercialized its product. Revenue will be generated following successful regulatory approvals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

i-Lumen Scientific develops the i-LUMEN AMD System, a non-invasive bioelectric stimulation medical device that delivers proprietary dual waveform microcurrent through the closed eyelid to restore transepithelial potential across the retinal pigment epithelium. The investigational device targets intermediate to advanced dry age-related macular degeneration and is administered in-office by ophthalmologists and retina specialists without anesthesia or incisions.

Product overview

i-Lumen Scientific offers a single core product: the i-LUMEN AMD System®, a non-invasive bioelectric therapy medical device. The system uses a proprietary dual waveform algorithm delivering microcurrent stimulation through the eyelid to restore retinal electrophysiology in patients with intermediate to advanced dry AMD. The company is supported by its clinical research program, including the completed i-SIGHT study and the ongoing i-SIGHT2 pivotal study (ClinicalTrials.gov: NCT05447650, NCT06662162).

Differentiator

Problem solved

Functional benefit

Brands

• i-LUMEN AMD System: Non-invasive bioelectric therapy system delivering microcurrent stimulation through the eyelid to restore retinal electrophysiology in patients with intermediate to advanced dry AMD.

Products and services

• i-LUMEN AMD System® A non-invasive bioelectric therapy medical device that delivers proprietary dual waveform microcurrent stimulation through the closed eyelid to restore transepithelial potential (TEP) across the retinal pigment epithelium, improve photoreceptor function, and support visual acuity in patients with intermediate to advanced dry age-related macular degeneration. It is administered in-office by ophthalmologists and retina specialists without anesthesia or incisions.

Quantifiable outcome

• 61.5% of patients achieved ≥10 letter improvement in BCVA by month 2
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Clinical Trial Sites (US, UK, Australia, New Zealand)coreStrategic or Co-development Partneri-SIGHT2 pivotal clinical study is being conducted at clinical trial sites across four countries including Texas Retina Associates in the US and London North West University Healthcare NHS Trust in the UK. These clinical partnerships are essential for regulatory approval pathway.
• Schepens Eye InstitutecoreStrategic or Co-development PartnerPreclinical research studies were conducted at Schepens Eye Institute evaluating neuroprotective signaling, photoreceptor survival, and inflammatory pathway modulation as part of the scientific foundation for the bioelectric therapy.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Alcon: Global ophthalmology leader that acquired LumiThera's Valeda system for $850M in late 2025, establishing the strategic acquisition benchmark for non-invasive dry AMD devices and representing both a competitor and potential acquirer of i-Lumen.
• Astellas Pharma: Acquired Iveric Bio and now markets Izervay (avacincaptad pegol), the second approved complement inhibitor for geographic atrophy, directly competing for the same advanced dry AMD patient population.
• Regeneron: Developer of Eylea (aflibercept), the standard-of-care anti-VEGF therapy for wet AMD and a major player in retinal disease whose physician relationships and commercial reach shape the dry AMD treatment landscape.
• Novartis: Global pharmaceutical company with a major ophthalmology franchise including Lucentis and Beovu, and the resources to acquire or compete with emerging dry AMD device and therapy developers.
• Genentech (Roche): Developer of Lucentis (ranibizumab) and a long-standing leader in retinal therapeutics, with extensive retina specialist relationships and ongoing pipeline programs in AMD.
• Apellis Pharmaceuticals: Developer of Syfovre (pegcetacoplan), the first FDA-approved complement inhibitor for geographic atrophy (advanced dry AMD) — a drug competitor that defines the standard of care i-Lumen's device must outperform or complement.
• Bausch + Lomb: Diversified ophthalmology company with retinal surgery and pharmaceutical offerings, and a potential strategic acquirer or distribution partner for novel dry AMD devices.

Direct peers

• LumiThera: Developer of the Valeda Light Delivery System, a non-invasive photobiomodulation device for dry AMD and the closest direct competitor to i-Lumen's i-LUMEN AMD System in the energy-based dry AMD device category.

Emerging players

• Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD, representing a potential future paradigm shift that could compete with or complement device-based dry AMD therapies.
• Ocular Therapeutix: Clinical-stage ophthalmology company developing sustained-release therapies for retinal diseases including wet AMD, with overlapping customer base of retina specialists who would also prescribe i-LUMEN.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i-Lumen Scientific